Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.

Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, Tang W. · 2019

Read Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. by Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, Tang W. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6714090.txt.

Introduction

Lu and co-authors reviewed the immune-suppressing surroundings of liver cancer. Hepatocellular carcinoma is rising as chronic hepatitis and cirrhosis spread. Surgery and chemotherapy exist, yet death rates stay high. The tissue around a tumor helps it grow by holding the immune system back.

The review describes the cells that do this work. They include tumor-linked macrophages, suppressor cells from bone marrow, neutrophils, fibroblasts, and regulatory T cells. Each type helps the tumor in its own way. The authors then survey current treatments aimed at these cells. They close with open questions for future immunotherapy research.

Catalog record

CREATORLu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, Tang W.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6714090

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities By Chen Lu, Dawei Rong, Betty Zhang, Wubin Zheng, Xuehao Wang, Ziyi Chen, Weiwei Tang Published in: Molecular Cancer DOI: 10.1186/s12943-019-1047-6 ABSTRACT Abstract Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues the mortality rate of HCC remains high. Immunotherapy is currently the new frontier of cancer treatment and the immunobiology of HCC is emerging as an area for further exploration. The tumor microenvironment coexists and interacts with various immune cells to sustain the growth of HCC. Thus, immunosuppressive cells play an important role in the anti-tumor immune response. This review will discuss the current concepts of immunosuppressive cells, including tumor-associated macrophages, marrow-derived suppressor cells, tumor-associated neutrophils, cancer-associated fibroblasts, and regulatory T cell interactions to actively promote tumorigenesis. It further elaborates on current treatment modalities and future areas of exploration. Keywords: Hepatocellular carcinoma, Macrophages, Myeloid suppressor cells, Immunotherapy INTRODUCTION Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide, with approximately 800,000 cases per year [1]. Most cases appear in the context of cirrhosis and are most often associated with chronic hepatitis B and hepatitis C virus infection. In the case of localized HCC, surgical resection, liver transplantation, and tumor ablation are potential cures. Advancements such as laparoscopic liver resection and living donor transplantation continue to develop and influence treatment options [2, 3]. For patients with locally advanced disease, interventional techniques such as transarterial chemoembolization or transradial radioembolization can provide disease control or lead to tumor regression and hypertrophy in future liver remnants [4, 5]. Systemic sorafenib has been shown to be effective in patients with severe cirrhosis who are not suitable for liver-directed therapy and patients with metastatic HCC who have slow disease progression. However, it only exerts a weak therapeutic effect [6, 7]. Therefore, a novel treatment strategy with different mechanisms from those of conventional treatments is needed to improve the prognosis of HCC. Since the approval of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) inhibitors for the treatment of melanoma, immunotherapy has emerged as a potential alternative treatment option in clinical practice. Get widespread attention. Malignant tumors [8]. HCC is an inflammation-driven disease with potentially chronic liver inflammation and cirrhosis, and a quarter of HCC cases express markers of inflammatory response. However, these tumors also have fewer chromosomal aberrations, suggesting a combination of immunological interventions may be more effective with conventional treatment of this disease [9]. Major immunotherapeutic strategies for HCC can be classified into five categories: adoptive cell therapies; cytokines; vaccines; immune checkpoint inhibitors; and oncolytic viruses. A phase II clinical trial using tremelimumab included 21 patients with advanced HCC, with partial response rates and disease control rates of 17.6 and 76.4%, respectively [10]. PD-1 is expressed on B cells, T cells, natural killer (NK) cells, and dendritic cells (DCs) [11]. The PD-1 monoclonal antibody (mAb) blocks receptor binding of PD-L1 and PD-L2 to activate immune cells [12]. The researchers found that the PD-1 inhibitor nivolumab activates a sustained tumor-specific immune response and that side effects are controllable [13]. Treatment with PD-1 and CTLA-4 can stimulate T cell activation to enhance tumor eradication. In the tumor microenvironment, non-malignant cells can help tumor cells to proliferate, invade and metastasize. The immunosuppressive features of tumor lesions participate not only as one of the major players inducing cancer progression but also a big challenge for effective immunotherapy. It has been found that immunosuppression associated with chronic inflammatory factors, such as growth factors, cytokines, and chemokines is generated by stroma and tumor cells [14, 15]. Multiple immune cells coexist and interact in a complex series of pathways that ultimately lead to tumor carcinogenesis. In the review, we will document some immunosuppressive cells, including tumor-associated macrophages (TAMs), marrow-derived suppressor cells (MDSCs), tumor-associated neutrophils (TANs), cancer-associated fibroblasts (CAFs) and regulatory T cells (Tregs) and their roles in cancer formation, which can lead to HCC. Tumor-associated macrophages TAMs inhibit anti-tumor immunity and promote tumor progression by expressing cytokines and chemokines. Preclinical studies have identified key pathways for TAMs recruitment, polarization and metabolism during tumor progression, and new therapies for these pathways can indirectly stimulate cytotoxic T-cell activation and recruitment [16–18]. Clinical trials of therapeutic agents currently promoting phagocytosis or inhibiting the survival, proliferation, transport or polarization of TAMs have shown improvement of cancer outcomes (Fig. 1). [Figure: Macrophage targeting strategy in HCC therapy. Preclinical studies have identified key pathways that regulate the recruitment, polarization, survival, and autophagy of TAMs during tumor progression. In addition, inhibition of macrophage-derived VEGF can inhibit tumor angiogenesis and progression. Targeting key receptors or signaling proteins can inhibit these macrophage properties and inhibit tumor progression. These molecular targets form the basis of several therapeutic HCC strategies currently being clinically developed to promote an effective anti-tumor immune response. Abbreviations: TAM, tumor-associated macrophages; Treg cells: regulatory T cells;VEGF, vascular endothelial growth factor] TAMs are significant components of the microenvironment in HCC and associated with a poor prognosis of HCC patients. TAMs expression and density have been assessed by immunohistochemical staining from 253 HCC patients and results showed that CD68+ TAMs were not associated with clinicopathologic features and prognosis in HCC. However, low presence of CD86+ TAMs and high presence of CD206+ TAMs were significantly associated with invasive tumor phenotypes and with poorer overall survival (OS) as well as reduced time to recurrence [19]. TAMs develop from monocytes to functional macrophages and acquire various immunosuppressive functions at each stage of its differentiation to maintain the tumor microenvironment [20]. Repolarization of TAMs towards an antitumor phenotype was one approach to contributing to tumor regression [21]. Yang Y et al. first demonstrated that tumor cell-derived Wnt ligand stimulates M2 to transduce the polarization of TAMs via classical Wnt/β-catenin signaling, which results in immunosuppression in HCC [22]. Therefore, blocking Wnt secretion in tumor cells and/or activation of Wnt/β-catenin signaling in TAMs may be a potential strategy for future HCC treatment. Previous literature has demonstrated that TAMs can produce a variety of chemokines, such as CCL17, CCL18 and CCL22, which attract Tregs cells to cancer sites, thereby impeding cytotoxic T cell activation [23, 24]. This may lead to a positive feedback loop between TAMs and Tregs, providing a new dimension to the immunosuppressive effects of cancer. TAMs in HCC can also attract Tregs to regulate the tumor microenvironment. This phenomenon was found by Zhou J that the intratumoral distribution of FoxP3+ Tregs were associated with high density TAMs. The anti-interleukin-10 (IL-10) antibody partially blocked this increase, suggesting that TAMs may trigger an increase in the population of FoxP3+ Treg cells in the tumor, thereby promoting the progression of HCC [25]. Mechanistically, Wu Q et al. recently confirmed that TREM-1+ TAMs can respond to hypoxia and tumor metabolites via the ERK/NF-κβ pathway leading to accumulation of CCR6+ Foxp3+ Tregs [26]. This study highlights hypoxia-induced tumor immunosuppression by TREM-1+ TAMs that attracts CCR6 + Foxp3 + Tregs, and TREM-1+ TAMs confers HCC resistance to Programmed cell death 1 ligand 1 (PD-L1) treatment. TAMs are able to produce angiogenic factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor and

Read the complete text